Sexual Health

Sexual health peptides represent a fundamentally different approach to treating sexual dysfunction compared to conventional medications like PDE5 inhibitors (sildenafil, tadalafil). While drugs like Viagra work peripherally — increasing blood flow to erectile tissue by inhibiting an enzyme that breaks down cyclic GMP — the peptides in this category act centrally, through the brain. They activate neural pathways involved in sexual desire and arousal at the level of the hypothalamus, meaning they address the motivational and psychological dimensions of sexual function rather than just the mechanical aspects. This central mechanism of action makes them relevant for both men and women, and particularly valuable in cases where desire itself is diminished.

PT-141 (Bremelanotide) is the most important peptide in this category and the only one with full FDA approval for a sexual health indication. Approved in 2019 under the brand name Vyleesi, it is indicated for premenopausal women with hypoactive sexual desire disorder (HSDD). PT-141 is a synthetic melanocortin receptor agonist that activates MC3R and MC4R receptors in the hypothalamus, stimulating dopaminergic pathways associated with sexual arousal. Its development history is notable — it originated from research into Melanotan II, a tanning peptide that was found to produce sexual arousal as a side effect. PT-141 was subsequently developed as a more targeted derivative. While only FDA-approved for women, it has been studied in men with erectile dysfunction and is used off-label in clinical settings for both sexes.

Kisspeptin is an endogenous neuropeptide that acts higher up the reproductive hormone cascade, at the hypothalamic level. It stimulates GnRH (Gonadotropin-Releasing Hormone) neurons, which in turn drive LH and FSH release — the master hormones controlling testosterone and estrogen production. Research has explored Kisspeptin's role in modulating both sexual arousal (through limbic system effects observed in fMRI studies) and reproductive hormone signaling. Unlike PT-141, Kisspeptin remains a research compound without regulatory approval for clinical use.

This is a small but significant category. The central-mechanism approach represents a genuine pharmacological advance over peripheral vasodilators, particularly for patients whose sexual dysfunction involves low desire rather than impaired physical response. PT-141's FDA approval gives it a level of clinical validation rare in the peptide space, though its side-effect profile (nausea being the most common) and the fact that it is approved only as an as-needed subcutaneous injection are practical considerations.